CMPX Stock Overview
A clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Compass Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.41 |
52 Week High | US$3.45 |
52 Week Low | US$1.15 |
Beta | 0.73 |
1 Month Change | -17.06% |
3 Month Change | -22.95% |
1 Year Change | -53.47% |
3 Year Change | -74.36% |
5 Year Change | n/a |
Change since IPO | -83.41% |
Recent News & Updates
Shareholder Returns
CMPX | US Biotechs | US Market | |
---|---|---|---|
7D | -4.1% | -0.4% | -0.6% |
1Y | -53.5% | 5.4% | 22.5% |
Return vs Industry: CMPX underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: CMPX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
CMPX volatility | |
---|---|
CMPX Average Weekly Movement | 10.1% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CMPX's share price has been volatile over the past 3 months.
Volatility Over Time: CMPX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 32 | Tom Schuetz | www.compasstherapeutics.com |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.
Compass Therapeutics, Inc. Fundamentals Summary
CMPX fundamental statistics | |
---|---|
Market cap | US$194.00m |
Earnings (TTM) | -US$45.44m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs CMPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CMPX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$45.44m |
Earnings | -US$45.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.33 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CMPX perform over the long term?
See historical performance and comparison